Application of Watson for Oncology in Hepatocellular Carcinoma Surgery
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Operative outcomes
研究概览
简要总结
The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.
详细描述
Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality. Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure. The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years≤ Age ≤80 years
- •Compling with the diagnosis criteria of complex hepatic carcinoma.
- •Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled
- •Preoperative liver function is Child - Pugh grade A or B.
- •The patients are volunteered for the study.
排除标准
- •Patients with mental illness.
- •Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)
- •The patients refused to take part in the study.
- •There are other co-existed malignant tumors.
- •Benign liver diseases
结局指标
主要结局
Operative outcomes
时间窗: intraoperative
Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded.
次要结局
- Postoperative survival(3 years)